JP2023538402A5 - - Google Patents

Info

Publication number
JP2023538402A5
JP2023538402A5 JP2023512327A JP2023512327A JP2023538402A5 JP 2023538402 A5 JP2023538402 A5 JP 2023538402A5 JP 2023512327 A JP2023512327 A JP 2023512327A JP 2023512327 A JP2023512327 A JP 2023512327A JP 2023538402 A5 JP2023538402 A5 JP 2023538402A5
Authority
JP
Japan
Application number
JP2023512327A
Other languages
Japanese (ja)
Other versions
JPWO2022038299A5 (https=
JP2023538402A (ja
Filing date
Publication date
Priority claimed from DE102020121965.2A external-priority patent/DE102020121965A1/de
Application filed filed Critical
Priority claimed from PCT/EP2021/073303 external-priority patent/WO2022038299A1/en
Publication of JP2023538402A publication Critical patent/JP2023538402A/ja
Publication of JP2023538402A5 publication Critical patent/JP2023538402A5/ja
Publication of JPWO2022038299A5 publication Critical patent/JPWO2022038299A5/ja
Pending legal-status Critical Current

Links

JP2023512327A 2020-08-21 2021-08-23 プロドラッグ特性を有する新規サイロシン誘導体 Pending JP2023538402A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102020121965.2 2020-08-21
DE102020121965.2A DE102020121965A1 (de) 2020-08-21 2020-08-21 Neuartige Derivate des Psilocins mit Prodrug-Eigenschaften
US202063118842P 2020-11-27 2020-11-27
US63/118,842 2020-11-27
PCT/EP2021/073303 WO2022038299A1 (en) 2020-08-21 2021-08-23 Novel psilocin derivatives having prodrug properties

Publications (3)

Publication Number Publication Date
JP2023538402A JP2023538402A (ja) 2023-09-07
JP2023538402A5 true JP2023538402A5 (https=) 2024-08-09
JPWO2022038299A5 JPWO2022038299A5 (https=) 2024-08-09

Family

ID=77739049

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512327A Pending JP2023538402A (ja) 2020-08-21 2021-08-23 プロドラッグ特性を有する新規サイロシン誘導体

Country Status (14)

Country Link
US (1) US20230295086A1 (https=)
EP (1) EP4200279A1 (https=)
JP (1) JP2023538402A (https=)
KR (1) KR20230054397A (https=)
CN (2) CN116075499B (https=)
AU (1) AU2021328726A1 (https=)
BR (1) BR112023003153A2 (https=)
CA (1) CA3188636A1 (https=)
CO (1) CO2023003282A2 (https=)
GB (2) GB2632056B (https=)
IL (1) IL300455A (https=)
MX (1) MX2023002133A (https=)
WO (1) WO2022038299A1 (https=)
ZA (1) ZA202301693B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
US12414936B2 (en) * 2017-02-09 2025-09-16 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound
CN114787363A (zh) 2019-10-01 2022-07-22 恩派瑞安神经科学公司 对真菌进行遗传工程化以调节色胺表达
PH12022551981A1 (en) 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
WO2022120181A1 (en) * 2020-12-03 2022-06-09 Mydecine Innovations Group Inc. Novel psilocin analog compositions and methods of synthesizing the same
US12343328B2 (en) 2020-12-09 2025-07-01 Caamtech, Inc. Dialkyl tryptamines and their therapeutic uses
US12534441B2 (en) 2021-01-15 2026-01-27 Beckley Psytech Limited Tryptamine analogues
EP4126857A1 (en) 2021-01-15 2023-02-08 Beckley Psytech Limited Ergoline analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
WO2023023347A1 (en) * 2021-08-20 2023-02-23 Terran Biosciences Inc. Prodrugs and derivatives of psilocin and uses thereof
EP4452939A4 (en) * 2021-12-24 2025-12-10 Kuleon Llc SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS
EP4457336A4 (en) 2021-12-31 2026-01-14 Empyrean Neuroscience Inc ORGANISMS GENETICALLY MODIFIED TO PRODUCE PSYCHOTROPIC ALKALOIDS
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US12065404B2 (en) 2022-03-18 2024-08-20 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
US11707447B1 (en) 2022-03-18 2023-07-25 Enveric Biosciences Canada Inc. C4-carbonothioate-substituted tryptamine derivatives and methods of using
EP4493544A4 (en) * 2022-03-18 2026-03-04 Enveric Biosciences Canada Inc TRYPTAMINE DERIVATIVE SALTS SUBSTITUTED WITH C4-CARBOXYLIC ACID AND C4-CARBONOTHIOATE AND METHODS OF USE
WO2023201293A2 (en) * 2022-04-13 2023-10-19 Caamtech, Inc. Tryptamine derivatives
EP4522167A1 (en) * 2022-05-10 2025-03-19 Mydecine Innovations Group Inc. Novel psilocin prodrug compounds and methods of synthesizing the same
WO2023219789A1 (en) * 2022-05-10 2023-11-16 Mydecine Innovations Group Inc. Novel psilocin prodrug compounds and methods of synthesizing the same
JP2025527296A (ja) * 2022-08-05 2025-08-20 マインドセット ファーマ インコーポレイテッド セロトニンに関する障害の治療に有用であるセロトニン作動薬としての3-エチルアミノ-インドール二量体
CA3261814A1 (en) * 2022-08-05 2024-02-08 Mindset Pharma Inc. 3-PYRROLIDINE-INDOLE DIMERS USED AS SEROTONINERGY AGENTS USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH THESE
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
WO2024055106A1 (en) * 2022-09-12 2024-03-21 Bionxt Solutions Inc. Amino acid and carbohydrate psilocin derivatives
US20240269113A1 (en) * 2023-01-24 2024-08-15 Compass Pathfinder Limited 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
EP4592276A1 (en) 2024-01-29 2025-07-30 Universität Heidelberg Novel acyloxymethyl prodrugs of psilocin and related 4-hydroxytryptamines obtained by an efficient synthetic approach

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3075992A (en) 1958-09-12 1963-01-29 Sandoz Ltd Esters of indoles
CH386442A (de) 1959-03-18 1965-01-15 Ciba Geigy Verfahren zur Herstellung neuer 7-Aza-benzimidazole
AU2005300045A1 (en) * 2004-09-27 2006-05-04 Organix, Inc. Indole compounds useful as serotonin selective agents
JP2010507585A (ja) * 2006-10-19 2010-03-11 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換インドール
US20180021326A1 (en) * 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
CA3052974A1 (en) * 2017-02-09 2018-08-16 CaaMTech, LLC Compositions and methods comprising a psilocybin derivative
PH12022551981A1 (en) * 2020-02-04 2023-10-16 Mindset Pharma Inc Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
WO2023023347A1 (en) * 2021-08-20 2023-02-23 Terran Biosciences Inc. Prodrugs and derivatives of psilocin and uses thereof
US20240269113A1 (en) * 2023-01-24 2024-08-15 Compass Pathfinder Limited 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES
US20250066394A1 (en) * 2023-08-25 2025-02-27 Compass Pathfinder Limited 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
JP2023538402A5 (https=)
BR112023012656A2 (https=)
CL2025004119A1 (es) Resistencia a la soja modificada por ingeniería genética.
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021016176A2 (https=)
BR102021015247A2 (https=)
BR102021015220A2 (https=)
BR102021014044A2 (https=)
BR102021014056A2 (https=)